As previously “undruggable” targets are finally being reached, the field of targeted protein degradation is truly changing the face of small molecule drug discovery. In the pursuit to demonstrate safe and effective clinical results, it's clear that a set of unique development challenges must be overcome for these novel therapeutics to achieve their seemingly limitless potential.

With 50+ speakers, 40+ new case studies, 3 dedicated streams, 6 technical deep-dives and 350+ attendees, TPD 2019 was the most comprehensive and the definitive guide for large pharma, innovative biotech and leading academic researchers to capitalize on this emerging therapeutic class and make targeted protein degradation a blockbuster therapeutic approach that improves patient outcomes.

Register your interest to receive agenda and speaker updates for the 2020 program as they are announced.